Sight Sciences (NASDAQ:SGHT) CTO David Badawi Sells 4,836 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 4,836 shares of Sight Sciences stock in a transaction on Friday, January 16th. The shares were sold at an average price of $6.62, for a total value of $32,014.32. Following the completion of the sale, the chief technology officer directly owned 1,912,273 shares of the company’s stock, valued at $12,659,247.26. This trade represents a 0.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

David Badawi also recently made the following trade(s):

• On Tuesday, January 6th, David Badawi sold 3,695 shares of Sight Sciences stock. The shares were sold at an average price of $7.48, for a total value of $27,638.60.
• On Monday, January 5th, David Badawi sold 3,051 shares of Sight Sciences stock. The shares were sold at an average price of $7.82, for a total value of $23,858.82.
• On Friday, January 2nd, David Badawi sold 2,914 shares of Sight Sciences stock. The stock was sold at an average price of $7.43, for a total value of $21,651.02.

Sight Sciences Stock Performance

Sight Sciences stock opened at $6.38 on Thursday. The company has a current ratio of 9.60, a quick ratio of 8.93 and a debt-to-equity ratio of 0.62. Sight Sciences, Inc. has a 1 year low of $2.03 and a 1 year high of $9.24. The company has a market cap of $337.31 million, a PE ratio of -7.09 and a beta of 2.42. The company’s 50-day moving average is $7.78 and its two-hundred day moving average is $5.33.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.10. The company had revenue of $19.91 million during the quarter, compared to analysts’ expectations of $17.74 million. Sight Sciences had a negative net margin of 60.63% and a negative return on equity of 61.59%. Equities analysts anticipate that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on SGHT. Piper Sandler set a $9.00 price target on Sight Sciences in a research note on Monday, January 5th. Morgan Stanley increased their target price on Sight Sciences from $6.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. Raymond James Financial set a $9.00 target price on Sight Sciences in a report on Monday, January 5th. Citigroup upped their price target on Sight Sciences from $5.50 to $9.10 and gave the company a “neutral” rating in a research note on Thursday, December 11th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sight Sciences in a research report on Monday, December 29th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $8.30.

Institutional Investors Weigh In On Sight Sciences

Large investors have recently modified their holdings of the business. Palumbo Wealth Management LLC bought a new position in shares of Sight Sciences during the 2nd quarter valued at about $328,000. Americana Partners LLC increased its stake in Sight Sciences by 42.4% during the 3rd quarter. Americana Partners LLC now owns 1,229,819 shares of the company’s stock worth $4,231,000 after purchasing an additional 365,901 shares in the last quarter. B Group Inc. raised its holdings in Sight Sciences by 11.6% during the 2nd quarter. B Group Inc. now owns 930,000 shares of the company’s stock worth $3,841,000 after buying an additional 96,400 shares during the period. Bank of Montreal Can bought a new position in Sight Sciences in the second quarter valued at approximately $49,000. Finally, Vanguard Personalized Indexing Management LLC lifted its stake in Sight Sciences by 38.9% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,888 shares of the company’s stock valued at $66,000 after buying an additional 4,453 shares in the last quarter. 55.51% of the stock is currently owned by institutional investors.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.